Calystegine A3 (Polyhydroxy Nortropane · Glycosidase Inhibitor · Dietary Alkaloid)
| Compound | Calystegine A3 (Calystegin A3) |
| Chemical class | Alkaloid — Tropane (Polyhydroxylated tropane; nortropane calystegine) |
| CAS | 117275-05-5 |
| Primary source | Solanum tuberosum (potato roots and tubers), Calystegia sepium, Convolvulaceae species |
| Key applications | Glycosidase inhibitor, plant defence metabolite; supplement research context; availability on request |
| Claim strength | Moderate (in vitro glycosidase inhibition); Emerging (in vivo) |
| Typical form | Research compound; naturally present in potato as minor alkaloid alongside solanine/chaconine |
| Buy from Herbuno | Request availability and bulk pricing → |
Name origin: From Calystegia sepium (hedge bindweed) where this class of alkaloids was first characterised. Calystegines are a family of polyhydroxylated nortropane alkaloids — distinct from the classical tropane alkaloids (atropine, cocaine) in having a hydroxylated nortropane ring system rather than the usual methyl-substituted tropane. They lack the ester side chains of atropine/cocaine and instead carry multiple hydroxyl groups on the ring. Distribution: Calystegines are distributed across the Convolvulaceae and Solanaceae plant families. In potatoes (Solanum tuberosum), calystegines occur alongside the solanine/chaconine glycoalkaloids but as separate, structurally distinct alkaloids. They also occur in tomato, belladonna, henbane, and numerous Convolvulaceae species. Pharmacological interest: Calystegines are potent glycosidase inhibitors — they mimic monosaccharide sugar configurations (the polyhydroxy nortropane resembles pyranose sugars) and competitively inhibit the enzymes that cleave glycosidic bonds. This makes them pharmacologically relevant for: (1) lysosomal storage disease research (glycosidase deficiency conditions); (2) antidiabetic research (alpha-glucosidase inhibition reducing glucose absorption); (3) antiviral research (glycoprotein processing inhibition). Supplement context: Calystegine A3 is not commercially available as a supplement ingredient but its occurrence in dietary plants (potato, tomato) at trace levels contributes to daily dietary glycosidase inhibitor exposure. Research interest is primarily pharmacological rather than supplement-commercial. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.
Evidence for Calystegine Applications
Glycosidase inhibition — mechanism: Calystegines inhibit multiple glycosidase enzymes including α-glucosidase, β-glucosidase, α-galactosidase, β-galactosidase, and β-glucuronidase at low micromolar concentrations. The polyhydroxylated nortropane mimics the transition-state conformation of glycosyl enzyme intermediates. This mechanism makes calystegines relevant for conditions involving glycosidase dysregulation. Claim strength: Moderate (in vitro mechanism well-characterised).
Lysosomal storage disease research: Certain calystegine analogues have been investigated as pharmacological chaperones for lysosomal storage diseases caused by glycosidase deficiencies (Gaucher disease — glucocerebrosidase deficiency; Pompe disease — acid alpha-glucosidase deficiency). Pharmacological chaperones stabilise misfolded mutant enzymes, partially restoring their activity. Calystegine B2 has shown some efficacy as a pharmacological chaperone for Gaucher disease in cellular models. Claim strength: Emerging (cellular models; early preclinical).
Antidiabetic potential: α-Glucosidase inhibition reduces the rate of glucose absorption from complex carbohydrates — the same mechanism as the pharmaceutical antidiabetic drugs acarbose and miglitol. Calystegine A3’s α-glucosidase inhibitory activity at low concentrations suggests dietary exposure from potato and tomato consumption contributes a small amount of glycosidase inhibitor activity. Claim strength: Emerging (in vitro; no human supplementation data).
Request availability and bulk pricing →
Browse Standardised Extract Powders →
Frequently Asked Questions — Calystegine
Are calystegines toxic?
At the concentrations present in dietary plants (potato, tomato) — approximately 1–10 µg/g fresh weight — calystegines are not considered toxic. They are distinct from solanine/chaconine (the toxic glycoalkaloids in potatoes) both structurally and pharmacologically. At high doses, glycosidase inhibition would cause GI effects (similar to acarbose’s GI side effects from intestinal glycosidase inhibition) — flatulence and GI cramping from undigested carbohydrates reaching the colon.
How do calystegines relate to atropine and cocaine structurally?
Calystegines share the tropane ring system with atropine and cocaine but differ fundamentally: (1) they are nortropanes (N-H rather than N-methyl); (2) they carry multiple hydroxyl groups instead of ester side chains; (3) they have no anticholinergic or local anaesthetic properties. The polyhydroxylated nortropane scaffold — resembling a sugar pyranose — is the feature that gives calystegines their glycosidase inhibitory activity, completely absent from classical tropane alkaloids.
Are calystegines present in commercial potato starch or flour?
Calystegines are water-soluble and present primarily in the peel and outer flesh of potato. Potato starch and flour processing involves extraction of starch from disrupted cells and washing, which substantially reduces calystegine content. Commercial potato starch has very low or undetectable calystegine content. Whole potato preparations (including peel) and potato juice have higher calystegine levels than processed starch products.
Can calystegines be used as natural acarbose alternatives?
In theory, the α-glucosidase inhibitory mechanism is analogous to acarbose (the pharmaceutical alpha-glucosidase inhibitor for type 2 diabetes). However, the potency of calystegines for intestinal α-glucosidase inhibition at realistic dietary exposure concentrations is far below therapeutic thresholds. For meaningful glycaemic control via α-glucosidase inhibition, pharmaceutical acarbose at controlled doses is far more appropriate. Mulberry leaf extract (containing 1-deoxynojirimycin, a potent glycosidase inhibitor also with a polyhydroxy structure) is a more commercially established botanical approach to this mechanism.
Related compounds: Solanine, Atropine, Cocaine, Hyoscyamine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery